Supplementary Data from Adoption of Decentralized Trial Elements in Cancer Clinical Trials Supporting FDA Approvals during COVID-19
Other
Patel, TH; Corneli, A; Balcazar, P; Lipset, C; Calvert, SB; Mervin-Blake, S; Nalawade, V; Kluetz, PG
June 17, 2026
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Citation
APA
Chicago
ICMJE
MLA
NLM
Patel, T. H., Corneli, A., Balcazar, P., Lipset, C., Calvert, S. B., Mervin-Blake, S., … Kluetz, P. G. (2026). Supplementary Data from Adoption of Decentralized Trial Elements in Cancer Clinical Trials Supporting FDA Approvals during COVID-19. https://doi.org/10.1158/1078-0432.32714145
Patel, Timil H., Amy Corneli, Pamela Balcazar, Craig Lipset, Sara B. Calvert, Sabrena Mervin-Blake, Vinit Nalawade, and Paul G. Kluetz. “Supplementary Data from Adoption of Decentralized Trial Elements in Cancer Clinical Trials Supporting FDA Approvals during COVID-19,” June 17, 2026. https://doi.org/10.1158/1078-0432.32714145.
Patel TH, Corneli A, Balcazar P, Lipset C, Calvert SB, Mervin-Blake S, et al. Supplementary Data from Adoption of Decentralized Trial Elements in Cancer Clinical Trials Supporting FDA Approvals during COVID-19. 2026.
Patel, Timil H., et al. Supplementary Data from Adoption of Decentralized Trial Elements in Cancer Clinical Trials Supporting FDA Approvals during COVID-19. 17 June 2026. Crossref, doi:10.1158/1078-0432.32714145.
Patel TH, Corneli A, Balcazar P, Lipset C, Calvert SB, Mervin-Blake S, Nalawade V, Kluetz PG. Supplementary Data from Adoption of Decentralized Trial Elements in Cancer Clinical Trials Supporting FDA Approvals during COVID-19. 2026.